Malignant solid neoplasm ERBB2-mutated · 4 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Trastuzumab deruxtecan monotherapy Variant #01 | ERBB2 | R 81 019 | 21d | ~15.5 mo | ~22.9 mo | ~2 | ~R 162 039 PFS proxy · indirect | 11 |
Pertuzumab and Trastuzumab Variant #01 | ERBB2 | R 78 133 | 21d | — | — | ~9 | ~R 243 771 indirect | — |
Trastuzumab emtansine monotherapy Variant #01 | ERBB2 | R 41 405 | 21d | ~7.4 mo | ~29.9 mo | ~14 | ~R 579 668 PFS proxy · indirect | 7 |
Neratinib monotherapy Variant #02 | ERBB2 | R 19 339 | 28d | — | — | ~52 | ~R 1 005 645 PFS proxy · indirect | 1 |
4 of 4 regimens shown